OmnigeniQ, an Australian start-up, has made a significant scientific advancement by unveiling what it claims to be the first deterministic computation of Cyclin-dependent kinase 5 (CDK5). This groundbreaking achievement was presented at the Biotech Showcase in San Francisco and marks a pivotal moment in the understanding of human proteins involved in neurological development and disease.
Utilizing a proprietary physics-based computational framework, OmnigeniQ successfully computed the three-dimensional structure, hydration shell, and surface topology of CDK5 directly from the fundamental principles of physics. This approach eliminates the need for structural templates, experimental approximations, or AI pattern-matching. The resulting model aligns with well-established features of CDK5 as seen through experimental methods such as X-ray crystallography but also enhances understanding by depicting the protein in a native, hydrated, and dynamic state, which traditional tools cannot capture.
Redefining Protein Visualization
This milestone is particularly noteworthy as it represents the first time human protein topology and behavior have been calculated and visualized directly from physics, rather than inferred from experimental or data-driven models. The implications for modern medicine are profound. The shape of proteins is crucial in determining how drugs interact with them, influencing factors such as binding sites and activation processes. CDK5’s role in neuronal signaling makes it a critical target for therapeutic development, especially given its association with various neurological and neurodegenerative disorders.
The innovative approach developed by OmnigeniQ allows for a realistic representation of proteins as living, hydrated entities in motion, reflecting their true state within the human body. This contrasts sharply with previous visualizations that depicted proteins as static or dehydrated entities, thereby unveiling molecular behaviors that existing experimental methods and AI-based tools have overlooked.
Implications for Drug Discovery
Proteins function as vital nanomachines that drive numerous biological processes, constantly adapting to their environments. Most modern medicines aim to target specific proteins, and a successful clinical trial often hinges on an accurate understanding of the protein’s three-dimensional geometry. With CDK5 being essential for neuron regulation, understanding its true physical structure is imperative for designing effective therapies that interact safely with this enzyme.
Tiffanwy Klippel-Cooper, co-founder and Chief Science Officer of OmnigeniQ, emphasized the breakthrough’s significance, stating, “Proteins have always been treated as objects to be imaged or inferred, rather than physical systems to be computed. The model I developed allows physical constraints to resolve the structure deterministically, showing that native protein conformations are a direct consequence of physics, not mere approximations.”
Echoing this sentiment, Jordana Blackman, co-founder and Chief Executive Officer, described the achievement as a defining moment for the company. “Knowing the true, dynamic structure of a protein allows for drug design with far higher specificity. This means fewer off-target effects, fewer failed candidates, and a faster path to viable therapies. The industry invests billions each year on molecules that fail due to a lack of understanding of their targets. Our physics-accurate protein computation can change that dynamic and revolutionize drug development.”
This achievement aligns with OmnigeniQ’s broader mission to create the world’s first holographic twin of the human body, a physics-accurate digital replica intended to make medicine more preventative, predictive, and precise. As this technology develops, it holds the potential to transform not only drug discovery and development but also the overall approach to understanding human biology.
